Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 12/20 | 0.41 |
| ▸ | MTOR | P42345 | 12/20 | 0.41 |
| ▸ | SCD | O00767 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16754659 | 0.91 | GSK3B (0.35) | PIK3CAMTORGRM5GSK3BDYRK1A | |
| SCHEMBL19361186 | 0.90 | MTOR (0.41) | PIK3CAMTORSCDDYRK1AFAAH | |
| SCHEMBL19699064 | 0.90 | ABL1 (0.36) | PIK3CAMTORGRM5GSK3BDYRK1A | |
| SCHEMBL17618510 | 0.90 | PIK3CA (0.41) | PIK3CAMTORGRM5GSK3BDYRK1A | |
| SCHEMBL20550423 | 0.89 | BMP1 (0.38) | PIK3CAMTORSCDGRM5GSK3B | |
| SCHEMBL16754479 | 0.89 | ABL1 (0.35) | PIK3CASCDGRM5GSK3BDYRK1A | |
| SCHEMBL19689743 | 0.88 | SCD (0.40) | PIK3CAMTORSCDGRM5GSK3B | |
| SCHEMBL17768254 | 0.87 | GRM5 (0.37) | PIK3CAMTORGRM5GSK3BDYRK1A | |
| SCHEMBL19361197 | 0.87 | FAAH (0.43) | GRM5TRPV1FAAH | |
| SCHEMBL17618581 | 0.87 | EGFR (0.43) | PIK3CAMTORSCDGSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-03-24 | — | — | US | disclosed |
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PIK3CA 4235/4885MTOR 442/4885SCD 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.